Molecular Glue Degraders Market
完整報告名稱與涵蓋範圍
Molecular Glue Degraders Market Size, Share & Trends Analysis Report, By Glue Type (Cereblon-Based Glue Degraders, Novel E3 Ligase Glue Degraders, Non-Degrading Molecular Glues and Stabilizers), By Therapeutic Area (Hematologic Malignancies, Solid Tumors, Immunology and Inflammation, Neurology and Other Areas), By Development Stage (Preclinical and Phase 1, Phase 2 and Phase 3, Approved and Commercial), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The molecular glue degraders market covers small molecules that induce proximity between an E3 ubiquitin ligase and a target protein to trigger its degradation, from cereblon-based glue degraders in late-stage trials to candidates exploiting novel ligases, along with non-degrading glues that stabilise or reshape protein complexes. Heterobifunctional PROTACs are addressed in the broader targeted protein degradation study and excluded here.
Molecular glues offer drug-like size, oral bioavailability and access to targets such as transcription factors that resist both inhibitors and larger degraders, which explains the intensity of investment since the mechanism of immunomodulatory drugs was elucidated. Late-stage cereblon modulators in multiple myeloma and lymphoma anchor near-term revenue, while GSPT1, IKZF and other glue programs progress in solid tumors and immunology. The discovery bottleneck, historically serendipity, is being addressed by rational glue design, DNA-encoded and phenotypic screening and AI-guided ligase mapping, which has generated a steady flow of alliances between platform biotechnology companies and large pharmaceutical partners.
The United States and Europe lead in originators and clinical programs, with China contributing an expanding set of cereblon-based candidates. Competition involves the cereblon franchise incumbents, glue-platform specialists and pharmaceutical groups building internal degrader capabilities.
The InsightAce study delivers revenue forecasts in US$ across all glue type, therapeutic area, development stage and end user and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Molecular Glue Degraders Market Snapshot
Chapter 4. Global Molecular Glue Degraders Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Glue Type Estimates & Trend Analysis
5.1. Glue Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Glue Type:
5.2.1. Cereblon-Based Glue Degraders
5.2.2. Novel E3 Ligase Glue Degraders
5.2.3. Non-Degrading Molecular Glues and Stabilizers
Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis
6.1. Therapeutic Area & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapeutic Area:
6.2.1. Hematologic Malignancies
6.2.2. Solid Tumors
6.2.3. Immunology and Inflammation
6.2.4. Neurology and Other Areas
Chapter 7. Market Segmentation 3: By Development Stage Estimates & Trend Analysis
7.1. Development Stage & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
7.2.1. Preclinical and Phase 1
7.2.2. Phase 2 and Phase 3
7.2.3. Approved and Commercial
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Hospitals and Cancer Centers
8.2.2. Specialty Pharmacies
Chapter 9. Molecular Glue Degraders Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Bristol Myers Squibb
11.2. Monte Rosa Therapeutics, Inc.
11.3. Novartis AG
11.4. C4 Therapeutics, Inc.
11.5. Kymera Therapeutics, Inc.
11.6. Nurix Therapeutics, Inc.
11.7. Roche Holding AG
11.8. Bayer AG (Vividion Therapeutics)
11.9. Neomorph, Inc.
11.10. Proxygen GmbH
11.11. Magnet Biomedicine, Inc.
11.12. Orionis Biosciences, Inc.
11.13. Triana Biomedicines, Inc.
11.14. Ranok Therapeutics
11.15. Eli Lilly and Company
圖表清單 List of Tables & Figures
Table 1. Global Molecular Glue Degraders Revenue Forecast by Glue Type, 2026-2035 (US$ Mn)
Figure 1. Global Molecular Glue Degraders Market Snapshot, 2026 & 2035
Table 2. Global Molecular Glue Degraders Revenue Forecast by Therapeutic Area, 2026-2035 (US$ Mn)
Figure 2. Global Molecular Glue Degraders Market Share by Therapeutic Area, 2026 & 2035
Table 3. Global Molecular Glue Degraders Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 3. Molecular Glue Degrader Pipeline by E3 Ligase, Target Class and Phase
Table 4. Global Molecular Glue Degraders Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Cereblon Modulator Franchise Transition and Late-Stage Readout Timeline
Table 5. North America Molecular Glue Degraders Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Molecular Glue Degraders Growth Opportunity Analysis
Table 6. Europe Molecular Glue Degraders Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Alliance Landscape Between Glue Discovery Platforms and Pharmaceutical Partners
Table 7. Asia Pacific Molecular Glue Degraders Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Molecular Glue Degraders Market Participants
Table 8. Latin America and Middle East & Africa Molecular Glue Degraders Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們